Spectrophotometric determination of lisinopril in commercial dosage forms using N-bromosuccinimide and chloranil

• Autorzy: Rahman N. , Siddiqui M. R. , Azmi S. N. H.

Warianty tytułu

PL

Spektrofotometryczne oznaczanie lizynoprilu w lekach handlowych przy użyciu N-bromosukcynimidu i chloranilu

• Języki publikacji: EN

Abstrakty

EN

Two simple, fast, sensitive, and economical spectrophotometric methods for quantification of lisinopril in drug formulations have been developed. Method A was based on the reaction between primary amino group of the drug with N-bromosuccinimide in acetone medium giving a yellow-colored product of maximum absorption at 353 nm. Method B was based on the formation of purple-colored charge transfer complex between the drug and chloranil in 1,4-dioxan-acetonitriIe medium. Beer's law was obeyed in the concentration ranges of 10-200 and 24-600 μg mLTwo simple, fast, sensitive, and economical spectrophotometric methods for quantification of lisinopril in drug formulations have been developed. Method A was based on the reaction between primary amino group of the drug with N-bromosuccinimide in acetone medium giving a yellow-colored product of maximum absorption at 353 nm. Method B was based on the formation of purple-colored charge transfer complex between the drug and chloranil in 1,4-dioxan-acetonitriIe medium. Beer's law was obeyed in the concentration ranges of 10-200 and 24-600 ug mL'1 with molar absorptivities of 1.40 x 10³ and 7.28 x 10² L^-1 mol cm'1 for methods A and B, respectively. Regression analysis yielded the following calibration equations: A = -2.44 x 10^-1 + 3.16 x 10^-1 C and A = 5.39 x 10^-4+ 1.65 x 10^-3C for methods A and B, respectively. For both calibration equations correlation coefficients were 0.9999. Intra- and inter-day precisions were lower than 1.60%. The optimum experimental conditions for the proposed methods have been investigated. Methods A and B have been successfully applied to the analysis of lisinopril in drug formulations. The results have been statistically compared to these obtained applying the British pharmacopoeia method with molar absorptivities of 1.40 x 10³ and 7.28 x 10² L^-1 mol cm^-1 for methods A and B, respectively. Regression analysis yielded the following calibration equations: A = -2.44 x 10^-1 + 3.16 x 10^-1 C and A = 5.39 x 10^-4+ 1.65 x 10^-3C for methods A and B, respectively. For both calibration equations correlation coefficients were 0.9999. Intra- and inter-day precisions were lower than 1.60%. The optimum experimental conditions for the proposed methods have been investigated. Methods A and B have been successfully applied to the analysis of lisinopril in drug formulations. The results have been statistically compared to these obtained applying the British pharmacopoeia method

PL

Opracowano dwie proste, szybkie, czule i ekonomiczne spektrofotometryczne metody ilościowego oznaczania lizynoprilu w preparatach farmaceutycznych. Metoda A jest oparta na reakcji picrwszorzędowej grupy aminowej leku z N-bromosukcynimidem w acetonie, w wyniku której powstaje żółty produkt wykazujący maksimum absorpcji przy df. fali 353 nm. Metoda B polega na tworzeniu purpurowego kompleksu z przeniesieniem iadunku miedzy lekiem a chloranilem w mieszaninie 1,4-dioksanu i acetonu. Prawo Beer'a było . spełnione w zakresie stężeń 10-200 i 24-600 1.40 x 10³; absorpcja molowa wynosiła 1.40 x 10³ and 7.28 x 10² L^-1 mol cm^-1, odpowiednio w przypadku metody A i B, W wyniku analizy regresji otrzymano dwa równania kalibracyjne A =-2,44 x 10^-4 + 3,16 x 10^-3 C oraz A = 5,39 x10^-4 + 1,65 x 10^-3 C, odpowiednio dla metody A i B. Obie metody zoptymalizowano i zastosowano z powodzeniem do analizy lizynoprilu w preparatach farmaceutycznych. Otrzymane wyniki porównano z wynikami uzyskanymi według Farmakopei Brytyjskiej.

Słowa kluczowe

EN

lisinopril; N-bromosuccinimide; chloranil; charge transfer; complexation reaction; drug; visible spectrophotometry

PL

lizynopril; N-bromosukcynimid; chloranil; przenoszenie ładunku; kompleksy; farmaceutyk; spektrofotometria

• Wydawca: Komitet Chemii Analitycznej PAN
• Czasopismo: Chemia Analityczna
• Rocznik: 2007
• Tom: Vol. 52, No. 3
• Strony: 465--480
• Opis fizyczny: Bibliogr. 32 poz.

Twórcy

autor

Rahman N.

autor

Siddiqui M. R.

autor

Azmi S. N. H.

• Department of Chemistry, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India,

Bibliografia

• 1. „ Martindale The Extra Pharmacopoeia ", 34th edn, Royal Pharmaceutical Society, London 2005, pp. 946-947.
• 2. Simpson K. and Jarvis B., Drugs, 59, 1149, (2000).
• 3. The United States Pharmacopoeia, 24th edn, The National Formulary 19, The United States Pharmacopoeial Convention, Inc., Rockville, MD, USA 2000.
• 4. El-Gindy A., Ashour A., Abdel-Fattah L. and Shabana, M.M., J. Pharm. Biomed. Anal., 25, 923 (2001).
• 5. Beasley C.A., Shaw J., Zhao Z. and Reed R.A., J. Pharm. Biomed. Anal., 37, 559 (2005).
• 6. Bonazzi D., Gotti R., Andrisano V. and Cavrini V., J. Pharm. Biomed. Anal., 16, 431 (1997).
• 7. El-Gindy A., Ashour A., Abdel-Fattah L. and Shabana, M.M., J. Pharm. Biomed. Anal., 25, 913 (2001).
• 8. Razzak O.A., Belal S.F., Bedair M.M., Barakat N.S. and Haggag R.S., J. Pharm. Biomed. Anal., 31, 701 (2003).
• 9. El-Enany N., Belal F. and Al-Ghannam S., Mikrochim. Acta, 141, 55 (2003).
• 10. Gotti R., Andrisano V. and Cavrini V., J. Pharm. Biomed. Anal., 22, 423 (2000).
• 11. Worland R J. and Jarrott B., J. Pharm. Sci., 75, 512 (1986).
• 12. Yuan A. S. and Gilbert J.D., J. Pharm. Biomed. Anal., 14, 773 (1996).
• 13. Ozer D. and Senel H., J. Pharm. Biomed. Anal., 21, 691 (1999).
• 14. Stanisz B., Acta Pol. Pharm., 61, 327 (2004).
• 15. Prasad C.V.N., Saha R.N. and Parimoo P., Pharm. Pharmacol. Commun., 5, 383 (1999).
• 16. Jain H.K. and Agrawal R.K., Indian Drugs, 37, 196 (2000).
• 17. Atmaca S., Tatar S. and Iskender G., Acta Pharm. Turc., 36, 13(1994).
• 18. Iskender G., and Yarenei B., Acta Pharm. Turc., 31, 5 (1995).
• 19. El-Yazbi F.A., Abdine H.H. and Shaalan R., J. Pharm. Biomed. Anal., 19, 819 (1999).
• 20. El-Emam A.A., Hamsen S.H., Moustafa M.A., El-Ashry S.M. and El-Sherbiny D.T., J. Pharm. Biomed. Anal., 34, 35 (2004).
• 21. Rajasekaran A. and Udayavani S., J. Indian Chem. Soc., 78, 485 (2001).
• 22. Rahman N., Anwar N. and Kashif M., Il Farmaco, 60, 605 (2005).
• 23. RahmanN., Singh M. and Hoda M.N., J. Braz. Chem. Soc., 16, 1001 (2005).
• 24. El-Gindy N.M., El-Bagry R.I., Aamer E.A. and Safawat H.M., J. Drug Res., 25,102 (2004).
• 25. International Conference on Harmonisation, ICH, Analytical procedures and methods validation, USA (2000).
• 26. British Pharmacopoeia, (2005) 1199-1200.
• 27. Hartmann C., Verbeke J.S., Penninckx W., Heyden Y.V., Vankeerber P. and Massart D.L., Anal. Chem., 67, 4491 (1995).
• 28. Barton D. and Ollis W.D., Amines and related compounds, in: Comprehensive Organic Chemistry: The synthesis and reactions of organic compounds, Vol. 2, (Sutherland I.O., Ed.) Pergamon press Ltd., UK 1979, p. 41.
• 29. Ross S.D., and Labes M.M., J. Am. Chem. Soc., 79, 76 (1957).
• 30. Ip D.P., DeMarco J.D. and Brooks M. A., Lisinopril in analytical profiles of drug substances and excipients, Vol. 21, [Brittain, H.G., Ed.], Academic Press, New York 1992, pp. 233-276.
• 31. Nalimov V. V., The Application of Mathematical Statistics to Chemical Analysis, Pergmon Press, Oxford 1963, pp. 167-189.
• 32. Canada Health Protection Branch, Drugs Directorate Guidelines: Acceptable methods, Ministry of National Health and Welfare, Draft, Canada (1992).